| Name | Title | Contact Details |
|---|
Alcon, A Division of Novartis, is the global leader in eye care. Our mission is to discover new ways to enhance sight and improve people`s lives. We were founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. Over the past 70 years, we have become the world`s leading eye care company through a combination of innovative research and development, strategic acquisitions, and partnerships with renowned third-party organizations. Today, we proudly reach more than 90 percent of the globe – operating in more than 75 countries, serving 180 markets and employing more than 18,000 people.
PTS Diagnostics is an innovative point-of-care diagnostics solutions provider that partners with patients and healthcare professionals to provide the right information at the right time to make the right decisions. The company`s name represents the three pillars upon which it has built its long-term success: People, Technology and Service.
PMI Labs is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MacuLogix is the only company to leverage the science of dark adaptation to help eliminate preventable blindness caused by AMD.
At Proof, we believe that knowledge is power—and good health is a necessity. We`re a health technology and diagnostics company that is currently developing a cutting-edge, CRISPR-based platform for point-of-care facilities to test for COVID-19, with ambitions to transform in-home diagnostics across a broad spectrum of health applications in the future. Proof is the brainchild of Professor Feng Zhang, a world-renowned molecular biologist and leader of a research lab at the Broad Institute of MIT and Harvard. In early 2020, Dr. Zhang along with Dr. Jonathan Gootenberg and Dr. Omar Abudayyeh of the McGovern Institute pivoted their focus towards combating the emergent threat of the COVID-19 pandemic. Pioneers of the CRISPR gene-editing technology, the three scientists dropped everything to face the global public health crisis head on. Combining CRISPR and RT-LAMP technologies in a novel approach, our scientific team is developing a simple, streamlined molecular diagnostics platform that can quickly test for the presence of the SARS-CoV-2 virus. Intended for use within clinics, pharmacies, schools, workplaces and eventually homes, our easy-to-use, lab-quality test platform is undergoing rigorous R&D protocols so that we can provide fast, accurate diagnostics that will help communities take control of their health. We want to transform the anxiety of waiting days for COVID-19 test results into the peace of mind of quickly knowing what steps to take next. Our first test system, which we`re designing to detect SARS-CoV-2, will enable us to fulfill our mission of helping restore a degree of normalcy to our world. From there, we aim to transform personalized health, and expand our diagnostic platform to detect other diseases, with the goal of providing actionable health information that will allow people to lead better, healthier lives. If you`re with us, reach out today.